Completed PHASE2 INTERVENTIONAL 2-arm NCT01535040

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

Randomized Placebo-Controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation Among Cancer Survivors

Sponsor: National Cancer Institute (NCI)

Conditions Breast Cancer Colorectal Cancer Lung Cancer Prostate Cancer Tobacco Use Disorder

Interventions memantine hydrochloride placebo

Updated 10 times since 2017 Last updated: Sep 7, 2021 Started: Aug 1, 2012 Primary completion: Feb 1, 2014 Completion: Feb 1, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and Colorectal Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Oct 2021 [monthly]

Completed PHASE2
Jan 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Oct 2018 — Jan 2020 [monthly]

Completed PHASE2
Aug 2018 — Oct 2018 [monthly]

Completed PHASE2
Jun 2018 — Aug 2018 [monthly]

Completed PHASE2
Aug 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Aug 2017 [monthly]

Completed PHASE2

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Wake Forest University Health Sciences

Data source: Wake Forest University Health Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Winston-Salem, United States